13th Workshop
Eurordis Round Table of Companies

"Patients' Access to OMPs, Innovative Pricing Schemes and National Measures in a Global Financial & Economic Crisis Environment"

13th December 2010
Les Salons de l’Aéro-Club de France
6, rue Galilée – 75116 Paris

Agenda

8:30 Welcome & coffee

MORNING: 9:00 - 12:45
Chairpersons:
Giulia Del Brenna (DG Enterprise, European Commission)
François Meyer (HAS – EUnetHTA)

9:00 – 9:10: Welcome address

9:10 – 9:40: “Comparative Pricing of the Most Common Orphan Drugs across Europe”, Steven Flostrand (Creativ-Ceutical, Luxembourg) 10’ question time

9:40 – 10:10: “Rare Disease National Alliances and the Issue of Patients’ Access to Orphan Drugs”, Fabrizia Bignami (EURORDIS); presented by Yann Le Cam (CEO of EURORDIS) 10’ question time

10:10 – 10:55: “Industry Representatives on their Recent Experiences regarding Pricing and Reimbursement at the National Level”, Andras Fehervary (Novartis, Italy), Katia Finck (Shire HGT, France), Zéra Tellier (LFB Biomédicaments, France) 10’ question time

10:55 – 11:25 COFFEE BREAK


11:55 – 12:50: “What are Pharmaceutical Companies and National Competent Authorities ready to do or accept to Reach a Common Agreement? What are the Limits of their Respective Efforts?” Panel discussion: speakers and panel members (Ri de Ridder – INAMI, Belgium)

LUNCH:
12:50 – 14:00
AFTERNOON: 14:00-17:00
Chairperson:
Yann Le Cam (EURORDIS)

14:00 – 14:15: Introduction to the parallel breakout sessions and presentation of the 4 discussion topics, Maria Mavris, EURORDIS

14:15 - 15:30: Parallel Breakout Sessions

Topics/groups:

1. Considering the first innovative approaches and concrete experiences, what new pricing scheme could be implemented for orphan drugs in the upcoming years? (e.g. secured sale volumes, risk sharing, …)
   Rapporteurs: Andrea Rappagliosi (GSK, Belgium), Bengt Jönsson (Stockholm School of Economics, Sweden).

2. Which coordinated mechanism of access to orphan drugs is needed at the European level?
   Rapporteurs: Giulia Del Brenna (EC-DG Enterprise, Belgium), Lugdivine Le Dez (Alexion, Belgium).

3. Some price containment measures are put in place in some Member States, how to handle the specific case of Orphan Drugs?
   Rapporteurs: Elke Hunsche (Actelion, Switzerland), Dorica Dan (Romanian Rare Disease National Alliance).

4. What best practices should be implemented at national level to ensure that stakeholders have a real interaction and participation in the different aspects related to patients’ access to orphan drug?
   Rapporteurs: Jean Mossman (HTAi Patient/Citizen Interest Group, UK), Raquel Luengo (Madrid HTA Agency, Spain).

15:30 – 16:15: Feedback from the parallel groups presented by the 4 rapporteurs

16:15 – 17:00: Discussion

17:00 End of Workshop